Evidence map›Paper›PMID 21256459›Full record

ArticleTranslational research : the journal of laboratory and clinical medicine2011

AVE4454B--a novel sodium-hydrogen exchanger isoform-1 inhibitor--compared less effective than cariporide for resuscitation from cardiac arrest.

Jeejabai Radhakrishnan, Julieta D Kolarova, Iyad M Ayoub, Raúl J Gazmuri

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in Translational research : the journal of laboratory and clinical medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02440373 (Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02440373 completednot on this mapstarted 2014, after this paper: background citation

Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome

TypeobservationalSponsorWake Forest University Health SciencesRan2014 to 2017Enrolled12ConditionsTrauma, Blunt Injury, Blunt Trauma, Accident
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. The Remaining Conundrum of the Role of the NaReviews in cardiovascular medicine · 2022
    Review
  2. Article
  3. Review
  4. Article
  5. Observational
  6. American journal of translational research · 2017
    Article
  7. Article
  8. Article
  9. Myocardial Dysfunction and Shock after Cardiac Arrest.BioMed research international · 2015
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jeejabai RadhakrishnanResuscitation Institute at Rosalind Franklin University of Medicine and Science and Medical Service, Section of Critical Care Medicine, Captain James A. Lovell Federal Health Care Center, North Chicago, Ill 60064, USA.
Julieta D Kolarova
Iyad M Ayoub
Raúl J Gazmuri
Captain James A. Lovell Federal Health Care Center · US

Funding

MYOCARDIAL PROTECTION BY NHE-1 INHIBITIONR01HL071728 · NHLBI · ROSALIND FRANKLIN UNIV OF MEDICINE &SCI · PI GAZMURI, RAUL JAIME · 2002 to 2005
$1.1M
NHLBI NIH HHS R01 HL071728NHLBI NIH HHS R01 HL71728
6 · The paper itself

Abstract

We compared the efficacy of the novel sodium-hydrogen exchanger (NHE-1) inhibitor AVE4454B with cariporide for resuscitation from ventricular fibrillation (VF) assessing the effects on left ventricular myocardial distensibility during chest compression, myocardial function after the return of spontaneous circulation, and survival. Three groups of 10 rats each were subjected to 10 min of untreated VF and resuscitation attempted by providing chest compression for up to 8 min with the depth of compression adjusted to attain an aortic diastolic pressure between 26 and 28 mmHg (to secure a coronary perfusion pressure above 20 mmHg) followed by electrical shocks. Rats received AVE4454B (1 mg/kg), cariporide (1 mg/kg), or vehicle control immediately before chest compression. We observed that NHE-1 inhibition (NHEI) preserved left ventricular myocardial distensibility during chest compression evidenced by less depth of compression required to attain the target aortic diastolic pressure corresponding to (mean ± standard deviation) 14.1 ± 1.1 mm in the AVE4454B group (P < 0.001 versus control), 15.0 ± 1.4 mm in the cariporide group (P < 0.01 versus control), and 17.0 ± 1.2 mm in controls. When the depth of compression was related to the coronary perfusion pressure generated-an index of left ventricular distensibility-only the cariporide group attained statistical significance. Postresuscitation, both compounds ameliorated myocardial dysfunction evidenced by lesser reductions in mean aortic pressure and the maximal rate of left ventricular pressure increase as well as earlier normalization of left ventricular end-diastolic pressure increases. This effect was associated with improved survival corresponding to 55% in the AVE4454B group (not significant) and 70% in the cariporide group (P < 0.01 versus control by Gehan-Breslow analysis) at 240 min postresuscitation. An inverse correlation was found between plasma cytochrome c and indices of left ventricular function at 240 min postresuscitation suggesting that NHEI exerts beneficial effects in part by attenuating mitochondrial injury. We conclude that cariporide is more effective than AVE4454B for resuscitation from cardiac arrest given its more prominent effect on preserving left ventricular myocardial distensibility and promoting survival.

Indexed as

AnimalsAnti-Arrhythmia AgentsDisease Models, AnimalGuanidinesHeart ArrestInhibitory Concentration 50MaleRatsRats, Sprague-DawleySodium-Hydrogen ExchangersSulfonesVentricular FibrillationVentricular Function, LeftAnti-Arrhythmia AgentscariporideGuanidinesSodium-Hydrogen ExchangersSulfones

Identifiers

PMID21256459
PMCPMC3651912
OpenAlexW1966970934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.